注册 登录  
 加关注
   显示下一条  |  关闭
温馨提示!由于新浪微博认证机制调整,您的新浪微博帐号绑定已过期,请重新绑定!立即重新绑定新浪微博》  |  关闭

liusongjifan2的博客

读书是同智者交流;读书是对神奇世界的探访;读书是和挚友娓娓谈心 !

 
 
 

日志

 
 

The Lancet-Oncogoy(2016-9-21)  

2016-09-21 19:07:05|  分类: 医学知识 |  标签: |举报 |字号 订阅

  下载LOFTER 我的照片书  |
Logo
Weekly Update
Sep 21, 2016
Weekly Features:
Keith R Porter/Science Photo Library
Research | Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study
This study assessed the activity and safety of ibrutinib, an oral covalent inhibitor of Bruton's tyrosine kinase, in relapsed or refractory patients with del17p chronic lymphocytic leukaemia or small lymphocytic lymphoma.
Read this Article →
Adrian Roots
Election 2016 | | Visit The Lancet's US Election hub
Visit our dedicated US Election 2016 hub for the latest research, comment, and opinion from across The Lancetfamily of journals, as well as regular podcasts. We will be highlighting the key health challenges facing the US up to election day and beyond.
Find out more →
Online First:
Patrice Latron/Eurelios/Look At Sciences/Sceince Photo Library
NEWS
Cord blood transplant improves outcomes in leukaemia
Patients with leukaemia or myelodysplastic syndrome who did not have a human leukocyte antigen (HLA) matched donor had reduced risks of death and relapse with an umbilical cord blood transplant than those who received unrelated-donor transplants, according to a new study by Filippo Milano and colleagues (Fred Hutchinson Cancer Research Center, Seattle, WA, USA).
Read this Report →
Arno Massee/Science Photo Library
NEWS
Mutational subgroups for oesophageal adenocarcinoma
Oesophageal adenocarcinoma can be divided into three molecular subtypes, according to a new study by Maria Secrier (Cambridge University, Cambridge, UK) and colleagues.
Read this Report →
ISM/Science Photo Library
NEWS
Carfilzomib therapy improves quality of life in multiple myeloma
Findings from a phase 3 trial suggest that in patients with relapsed multiple myeloma, carfilzomib in combination with lenalidomide and dexamethasone (KRd) significantly improves quality of life without adversely affecting symptoms, compared with lenalidomide and dexamethasone alone (Rd).
Read this Report →
Susumu Nishinaga/Science Photo Library
COMMENT
Bevacizumab in colorectal cancer: it should have worked
Leonard Saltz comments on the findings of the QUASAR 2 trial.
Read this Comment →
ARTICLES
Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial
Antiangiogenic agents have established efficacy in the treatment of metastatic colorectal cancer. This study investigated whether bevacizumab could improve disease-free survival in the adjuvant setting after resection of the primary tumour.
Read this Article →
Pr J Bernard/Cnri/Science Photo Library
COMMENT
A selective histone deacetylase inhibitor for myeloma
Guy Pratt comments on Andrew Yee and colleagues' phase 1b trial, which assessed safety and dosing of a selective HDAC6 inhibitor, ricolinostat, in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma.
Read this Comment →
ARTICLES
Ricolinostat plus lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a multicentre phase 1b trial
Motivated by findings from preclinical studies showing potent synergistic activity with ricolinostat and lenalidomide, this study aimed to assess the safety and preliminary activity of the combination of ricolinostat with lenalidomide and dexamethasone in relapsed or refractory multiple myeloma.
Read this Article →
Keith R Porter/Science Photo Library
COMMENT
Ibrutinib holds promise for patients with 17p deletion CLL
Paolo Ghia comments on the findings of the RESONATE-17 study.
Read this Comment →
ARTICLES
Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study
This study assessed the activity and safety of ibrutinib, an oral covalent inhibitor of Bruton's tyrosine kinase, in relapsed or refractory patients with del17p chronic lymphocytic leukaemia or small lymphocytic lymphoma.
Read this Article →
Announcements:
Stay Connected
Stay Connected
If you would prefer not to receive these weekly updates, but wish to continue receiving the monthly Table of Contents alert, please click here:
Unsubscribe from Weekly Updates →

Follow us on Twitter
For all the very latest news, comment, and research follow The Lancet Oncology on Twitter.
Follow us →
The Lancet Choice
Access 5 articles from The Lancet Clinic for just $49.00
The Lancet Choice is a new payment option that gives you the freedom to access 5 premium articles of your choice from The Lancet Clinic's ever-growing collection of disease pages - all for the reduced introductory rate of $49.00.
Find out more →
This email has been sent from The Lancet, Elsevier Limited, The Boulevard, Langford Lane, Kidlington, Oxford, OX5 1GB, registered in England with registered number 1982084. 

Copyright ? 2016 Elsevier Limited. All rights reserved. THE LANCET ? is a registered trademark of RELX Intellectual Properties SA, used under license. 

To unsubscribe from The Lancet Oncology Weekly Updates, but continue receiving the monthly Table of Contents alert, please click here →

To unsubscribe from all Table of Contents alerts, please edit your mailing preferences by logging in to your TheLancet.com account: 

Update mailing preferences
The Lancet-Oncogoy(2016-9-21) - liusongjifan2 - liusongjifan2的博客 The Lancet-Oncogoy(2016-9-21) - liusongjifan2 - liusongjifan2的博客
  评论这张
 
阅读(6)| 评论(0)
推荐 转载

历史上的今天

在LOFTER的更多文章

评论

<#--最新日志,群博日志--> <#--推荐日志--> <#--引用记录--> <#--博主推荐--> <#--随机阅读--> <#--首页推荐--> <#--历史上的今天--> <#--被推荐日志--> <#--上一篇,下一篇--> <#-- 热度 --> <#-- 网易新闻广告 --> <#--右边模块结构--> <#--评论模块结构--> <#--引用模块结构--> <#--博主发起的投票-->
 
 
 
 
 
 
 
 
 
 
 
 
 
 

页脚

网易公司版权所有 ©1997-2017